A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer
The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.
100 Clinical Results associated with Sopherion Therapeutics LLC
0 Patents (Medical) associated with Sopherion Therapeutics LLC
100 Deals associated with Sopherion Therapeutics LLC
100 Translational Medicine associated with Sopherion Therapeutics LLC